Nitrite Promotes ROS Production to Potentiate Cefoperazone-Sulbactam-Mediated Elimination to Lab-Evolved and Clinical-Evolved Pseudomonas aeruginosa

Nitrite Promotes ROS Production to Potentiate Cefoperazone-Sulbactam-Mediated Elimination to Lab-Evolved and Clinical-Evolved Pseudomonas aeruginosa

ABSTRACT Cefoperazone-sulbactam (SCF)-resistant Pseudomonas aeruginosa poses a big challenge in the use of SCF to treat infection caused by the pathogen. We have recently shown exogenous nitrite-enabled killing of naturally and artificially evolved Pseudomonas aeruginosa strains (AP-RCLIN-EVO and AP...

Full description

Bibliographic Details
Main Authors:	Su-fang Kuang, Xia Li, Ding-Yun Feng, Wen-Bin Wu, Hui Li, Bo Peng, Xuan-xian Peng, Zhuang-gui Chen, Tian-tuo Zhang
Format:	Article
Language:	English
Published:	American Society for Microbiology 2022-08-01
Series:	Microbiology Spectrum
Subjects:	Pseudomonas aeruginosa antibiotic resistance cefoperazone-sulbactam electron transport chain nitrite reprogramming metabolomics
Online Access:	https://journals.asm.org/doi/10.1128/spectrum.02327-21

Similar Items

Coagulopathy Induced by Cefoperazone/Sulbactam in a Geriatric Patient
by: Ergenekon Karagoz, et al.
Published: (2015-12-01)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
by: Xi-kang Tang, et al.
Published: (2022-03-01)

Differential Proteomic and Genomic Comparison of Resistance Mechanism of Pseudomonas aeruginosa to Cefoperazone Sodium/Sulbactam Sodium
by: SHUANGQI CAI, et al.
Published: (2022-09-01)

Antimicrobial activities of cefoperazone-sulbactam in comparison to cefoperazone against clinical organisms from medical centers in Taiwan
by: Tsung-Ta Chiang, et al.
Published: (2016-01-01)

Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder
by: Miao W, et al.
Published: (2023-09-01)

Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam
by: Yan-Jing Qu, et al.
Published: (2016-12-01)

In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products
by: Ming-Jen Sheu, et al.
Published: (2020-02-01)

Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease
by: Chien-Ming Chao, et al.
Published: (2022-04-01)

Repressed Central Carbon Metabolism and Its Effect on Related Metabolic Pathways in Cefoperazone/Sulbactam-Resistant Pseudomonas aeruginosa
by: Yue-tao Chen, et al.
Published: (2022-03-01)

Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam
by: Ling Zhou, et al.
Published: (2019-11-01)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
by: Xueting Wang, et al.
Published: (2023-02-01)

Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in Enterobacteriaceae Due to Narrow-Spectrum β-Lactamases as Well as Omp Mutation
by: Yang Fengzhen, et al.
Published: (2022-06-01)

Antimicrobial Efficacy of Cefoperazone-Salbactam Plus Tigecycline versus Cefoperazone-Salbactam Against Respiratory Pathogens and Their Effect on Laboratory Indices
by: Sundas Shaukat, et al.
Published: (2023-07-01)

Case report: Cefoperazone-sulbactam induced Kounis syndrome and cardiogenic shock
by: Peng Ding, et al.
Published: (2022-11-01)

Case Report: Drug-Induced Immune Haemolytic Anaemia Caused by Cefoperazone-Tazobactam/ Sulbactam Combination Therapy
by: Yuanjun Wu, et al.
Published: (2021-08-01)

Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii
by: Kanchanasuwan S, et al.
Published: (2021-03-01)

Hypersensitivity vasculitis induced by cefoperazone/sulbactam
by: Ariturk Ender, et al.
Published: (2003-01-01)

Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies
by: Lei Zhang, et al.
Published: (2023-06-01)

Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study
by: Ruiqiu Zhang, et al.
Published: (2023-06-01)

Erratum: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies
by: Frontiers Production Office
Published: (2024-01-01)

Comparison of commonly used antimicrobial susceptibility testing methods for evaluating susceptibilities of clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli to cefoperazone–sulbactam
by: Shio-Shin Jean, et al.
Published: (2017-08-01)

Tracking cefoperazone/sulbactam resistance development in vivo in A. baumannii isolated from a patient with hospital-acquired pneumonia by whole-genome sequencing
by: Xiaofen Liu, et al.
Published: (2016-08-01)

Quorum Sensing Inhibiting Activity of Cefoperazone and Its Metallic Derivatives on Pseudomonas aeruginosa
by: Nourhan G. Naga, et al.
Published: (2021-09-01)

Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae
by: Xi-Wei Ji, et al.
Published: (2022-07-01)

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against <i>Acinetobacter baumannii</i> in Patients with Hospital-Acquired Pneumonia
by: Yingjie Zhou, et al.
Published: (2022-05-01)

Cefoperazone Induced Gastrointestinal Bleeding
by: Goutham Reddy Katukuri, et al.
Published: (2016-08-01)

Comparative pharmacokinetics of cefoperazone following intravenous and intramuscular administration in goats
by: Taha Attia, et al.
Published: (2015-06-01)

Assessment of Effective Antimicrobial Regimens and Mortality-Related Risk Factors for Bloodstream Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
by: Gu S, et al.
Published: (2023-05-01)

Cefoperazone induced hypersensitivity vasculitis
by: Katiyar Subodh, et al.
Published: (2009-01-01)

Perfil de Sulbactam/ Ampicilina y Sulbactam/Cefoperazona en la Práctica Clínica
by: Guillermo Prada
Published: (2021-10-01)

Cefoperazone metal complexes and their antimicrobial investigations
by: Mehmet Emin ÇINAR, et al.
Published: (2021-05-01)

Severe Wound Infection due to Acinetobacter baumannii After a Human Bite
by: Gökhan KARAHAN, et al.
Published: (2019-12-01)

The known-unknown: third- and fourth-generation cephalosporins combined with sulbactam
by: Stetsiouk O.U., et al.
Published: (2023-03-01)

Determination of cefotaxime, cefoperazone, ceftazidime and cefadroxil using surface plasmon resonance band of silver nanoparticles
by: Hesham Salem, et al.
Published: (2018-11-01)

Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing <i>Enterobacterales</i> and Differentiation of Carbapenem-Resistant <i>Enterobacterales</i>
by: Kentarou Takei, et al.
Published: (2023-07-01)

Bloodstream infections caused by ST2 Acinetobacter baumannii: risk factors, antibiotic regimens, and virulence over 6 years period in China
by: Kaihang Yu, et al.
Published: (2021-01-01)

<i>Acinetobacter baumannii</i> Resistance to Sulbactam/Durlobactam: A Systematic Review
by: Luigi Principe, et al.
Published: (2022-12-01)

Hypothermia from a two‐component mixture comprising Amoxicillin and Sulbactam
by: Tung Anh Dinh Duong, et al.
Published: (2020-06-01)

Vibrational Analysis and Concentration Dependent SERS Study of Cefoperazone
by: Stefana Ana-Maria Faur, et al.
Published: (2024-03-01)

Cefoperazone rapidly and sensitive quantitative assessment via a validated RP-HPLC method for different dosage forms, in-use stability, and antimicrobial activities
by: Mostafa F. Al-Hakkani, et al.
Published: (2023-07-01)